Search for other papers by Annalisa Blasetti in
Google Scholar
PubMed
Search for other papers by Valeria Castorani in
Google Scholar
PubMed
Search for other papers by Nella Polidori in
Google Scholar
PubMed
Search for other papers by Ilaria Mascioli in
Google Scholar
PubMed
Search for other papers by Francesco Chiarelli in
Google Scholar
PubMed
Search for other papers by Cosimo Giannini in
Google Scholar
PubMed
Objective
Linear growth is impaired in children with type 1 diabetes (T1D) and poor metabolic control. A good metabolic control is a key therapeutic goal to prevent vascular complications and also to ensure appropriate anthropometric development during childhood. In this study, we aimed to identify and characterize the effects of glycemic variability on linear growth in children with T1D.
Methods
Data from 144 prepubertal children with T1D were evaluated. Anthropometric measurements (weight, weight-SDS, height, height-SDS, BMI, BMI-SDS) were collected and glycosylated hemoglobin (HbA1c) was measured at admission and every 4 months over a 2-year period. Glycemic variability indexes (glycemic coefficient of variation (CV), glycemic CV percentage (CV%), and the product between HbA1c-mean and HbA1c-SDS/100 (M*SDS-HbA1c/100)) were calculated. According to height-SDS changes after 2 years of follow-up, the study population was divided into three tertile groups and differences across groups were investigated for variables of interest.
Results
The three groups were similar in terms of age, gender, and follow-up period. After 2 years, all prepubertal children showed a significant positive trend of anthropometric data. Across the three tertile groups, HbA1c-SDS, CV, CV%, and M*SDS-HbA1c significantly decreased from the first to the third tertile of height-SDS. During follow-up, children with lower Δheight-SDS values reported higher values of HbA1c-SDS, CV, CV%, and M*SDS-HbA1c than subjects with higher linear growth.
Conclusions
Glycemic variability correlates with linear growth in children with T1D. Low glycemic variability indexes were reported in higher height-SDS tertiles. Δheight-SDS is inversely correlated with glycemic CV, CV%, and M*SDS-HbA1c.
Search for other papers by Qian Deng in
Google Scholar
PubMed
Search for other papers by Yue Zhu in
Google Scholar
PubMed
Search for other papers by Mengmeng Zhang in
Google Scholar
PubMed
Search for other papers by Aihua Fei in
Google Scholar
PubMed
Search for other papers by Jiaqi Liang in
Google Scholar
PubMed
Search for other papers by Jinjin Zheng in
Google Scholar
PubMed
Search for other papers by Qingping Zhang in
Google Scholar
PubMed
Search for other papers by Tong Cheng in
Google Scholar
PubMed
Search for other papers by Xia Ge in
Google Scholar
PubMed
Diabetes is a complex metabolic disease. In recent years, diabetes and its chronic complications have become a health hotspot of global concern. It is very important to find promising therapeutic targets and directions. Ferroptosis is a new type of programmed cell death that is different from cell necrosis, apoptosis, and autophagy. Ferroptosis is mainly characterized by iron-dependent lipid peroxidation. With the reduction of the anti-oxidative capacity of cells, the accumulated reactive lipid oxygen species will cause oxidative cell death and lead to ferroptosis at lethal levels. Recent studies have shown that ferroptosis plays an important regulatory role in the initiation and development of diabetes, as well as various complications of diabetes. In this review, we will summarize new findings related to ferroptosis and diabetic complications and propose ferroptosis as a potential target for treating diabetic complications.
Search for other papers by Clemens Kamrath in
Google Scholar
PubMed
Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
Search for other papers by Alexander Eckert in
Google Scholar
PubMed
Search for other papers by Birgit Rami-Merhar in
Google Scholar
PubMed
Search for other papers by Sebastian Kummer in
Google Scholar
PubMed
Search for other papers by Martin Wabitsch in
Google Scholar
PubMed
Search for other papers by Katharina Laubner in
Google Scholar
PubMed
Search for other papers by Florian Kopp in
Google Scholar
PubMed
Search for other papers by Silvia Müther in
Google Scholar
PubMed
Search for other papers by Steffen Mühldorfer in
Google Scholar
PubMed
Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
Search for other papers by Reinhard W Holl in
Google Scholar
PubMed
Objective
To investigate the frequency, treatment, and outcome of patients with diabetes due to severe insulin resistance syndromes (SIRS).
Research Design and Methods
Based on data from the multicenter prospective Diabetes Registry DPV, we analyzed diagnosis, treatment, and outcome of 636,777 patients with diabetes from 1995 to 2022.
Results
Diabetes due to SIRS was documented in 67 cases (62.7% females), 25 (37%) had lipodystrophies (LD) and 42 (63%) had congenital defects of insulin signaling. The relative frequency compared to type 1 diabetes (T1D) was about 1:2300. Median age at diabetes diagnosis in patients with SIRS was 14.8 years (interquartile range (IQR) 12.8–33.8).
A total of 38 patients with SIRS (57%) received insulin and 34 (51%) other antidiabetics, mostly metformin. As high as 16% of patients with LD were treated with fibrates. Three out of eight patients with generalized LD (37.5%) were treated with metreleptin and one patient with Rabson–Mendenhall syndrome was treated with recombinant insulin-like growth factor 1.
The median glycated hemoglobin level at follow-up was 7.1% (54 mmol/mol). Patients with LD had higher triglycerides than patients with T1D and T2D (P < 0.001 and P = 0.022, respectively), and also significantly higher liver enzymes and lower high-density lipoprotein cholesterol than patients with T1D (P < 0.001).
Patients with insulin receptor disorders were significantly less likely to be treated with antihypertensive medication than patients with T2D (P = 0.042), despite having similar levels of hypertension.
Conclusions
Diabetes due to SIRS is rarely diagnosed and should be suspected in lean children or young adults without classical T1D. Awareness of cardiovascular risk factors in these patients should be raised.
Search for other papers by Chenyu Jiang in
Google Scholar
PubMed
Search for other papers by Mi Zhou in
Google Scholar
PubMed
Search for other papers by Huai Bai in
Google Scholar
PubMed
Search for other papers by Meng Chen in
Google Scholar
PubMed
Search for other papers by Chunyi Yang in
Google Scholar
PubMed
Search for other papers by Kaifeng Hu in
Google Scholar
PubMed
Search for other papers by Yujie Wu in
Google Scholar
PubMed
Search for other papers by Qingqing Liu in
Google Scholar
PubMed
Search for other papers by Yangyu Zhao in
Google Scholar
PubMed
Search for other papers by Xinghui Liu in
Google Scholar
PubMed
Search for other papers by Ping Fan in
Google Scholar
PubMed
Oxidative stress plays an important role in the pathophysiology of gestational diabetes mellitus (GDM). We investigated the relationship between NADPH oxidase p22phox subunit (CYBA) C242T (rs4673) and myeloperoxidase (MPO) G-463A (rs2333227) genetic variants and GDM in 719 patients with GDM and 1205 control women. Clinical, metabolic, and oxidative stress parameters were analyzed. We found that frequencies of the A allele (15.6% vs 12.3%) and GA + AA genotype (28.5% vs 23.2%) of the MPO G-463A variation were significantly higher in patients with GDM than in the control women (OR = 1.318, 95% CI: 1.068–1.625, P = 0.010 for the dominant model; OR = 1.999, 95% CI: 1.040–3.843, P = 0.034 for the recessive model; OR = 1.320, 95% CI: 1.095–1.591, P = 0.004 for the allele model). Genotype GA + AA remained a significant predictor of GDM in a logistic regression model including age and BMI at delivery (OR = 1.282, 95% CI: 1.037‒1.583, P = 0.021). Furthermore, the ‒463A allele was associated with higher TG and the 242T allele was related to higher pre-pregnancy BMI and oxidative stress index in all subjects (P < 0.05). The 242T allele was also associated with higher homeostatic model assessment of insulin resistance but lower serum total antioxidant capacity in patients with GDM (P < 0.05). We conclude that the MPO G-463A, but not the CYBA C242T, genetic variation is associated with an increased risk of GDM in Chinese women. These two genetic polymorphisms may be linked to obesity, dyslipidemia, insulin resistance, and oxidative stress.
Weihai Institute for Bionics, Jilin University, Weihai, China
Search for other papers by Xiaohui Weng in
Google Scholar
PubMed
Search for other papers by Gehong Li in
Google Scholar
PubMed
Search for other papers by Ziwei Liu in
Google Scholar
PubMed
Search for other papers by Rui Liu in
Google Scholar
PubMed
Search for other papers by Zhaoyang Liu in
Google Scholar
PubMed
Search for other papers by Songyang Wang in
Google Scholar
PubMed
Search for other papers by Shishun Zhao in
Google Scholar
PubMed
Search for other papers by Xiaotong Ma in
Google Scholar
PubMed
College of Biological and Agricultural Engineering, Jilin University, Changchun, China
Key Laboratory of Bionic Engineering, Ministry of Education, Jilin University, Changchun, China
Search for other papers by Zhiyong Chang in
Google Scholar
PubMed
Studies have found differences in the concentration of volatile organic compounds in the breath of diabetics and healthy people, prompting attention to the use of devices such as electronic noses to detect diabetes. In this study, we explored the design of a non-invasive diabetes preliminary screening system that uses a homemade electronic nose sensor array to detect respiratory gas markers. In the algorithm part, two feature extraction methods were adopted, gradient boosting method was used to select promising feature subset, and then particle swarm optimization algorithm was introduced to extract 24 most effective features, which reduces the number of sensors by 56% and saves the system cost. Respiratory samples were collected from 120 healthy subjects and 120 diabetic subjects to assess the system performance. Random forest algorithm was used to classify and predict electronic nose data, and the accuracy can reach 93.33%. Experimental results show that on the premise of ensuring accuracy, the system has low cost and small size after the number of sensors is optimized, and it is easy to install on in-car. It provides a more feasible method for the preliminary screening of diabetes on in-car and can be used as an assistant to the existing detection methods.
Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, UK
Search for other papers by Benjamin D Maylor in
Google Scholar
PubMed
Search for other papers by Julia K Zakrzewski-Fruer in
Google Scholar
PubMed
Search for other papers by Charlie J Orton in
Google Scholar
PubMed
Centre for Physical Activity in Health and Disease, Brunel University London, Uxbridge, UK
Division of Sport, Health and Exercise Sciences, Department of Life Sciences, Brunel University London, Uxbridge, UK
Search for other papers by Daniel P Bailey in
Google Scholar
PubMed
A single exercise session can affect appetite-regulating hormones and suppress appetite. The effects of short, regular physical activity breaks across the day on appetite are unclear. This study investigated the effects of breaking up sitting with high-intensity physical activity vs a single bout of moderate-intensity exercise and prolonged sitting on appetite control. In this randomised crossover trial, 14 sedentary, inactive adults (7 women) completed 3, 8-h experimental conditions: (i) prolonged sitting (SIT); (ii) 30 min of moderate-intensity exercise followed by prolonged sitting (EX-SIT), and (iii) sitting with 2 min 32 s of high-intensity physical activity every hour (SIT-ACT). Physical activity energy expenditure was matched between EX-SIT and SIT-ACT. Subjective appetite was measured every 30 min with acylated ghrelin and total peptide-YY (PYY) measured hourly in response to two standardised test meals. An ad libitum buffet meal was provided at the end of each condition. Based on linear mixed model analysis, total area under the curve for satisfaction was 16% higher (P = 0.021) and overall appetite was 11% lower during SIT-ACT vs EX-SIT (P = 0.018), with no differences between SIT-ACT and SIT. Time series analysis indicated that SIT-ACT reduced subjective appetite during the majority of the post-lunch period compared with SIT and EX-SIT, with some of these effects reversed earlier in the afternoon (P < 0.05). Total PYY and acylated ghrelin did not differ between conditions. Relative energy intake was 760 kJ lower during SIT-ACT vs SIT (P = 0.024). High-intensity physical activity breaks may be effective in acutely suppressing appetite; yet, appetite-regulating hormones may not explain such responses.
Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, Xiamen, China
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Search for other papers by Weiwei He in
Google Scholar
PubMed
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Search for other papers by Caoxin Huang in
Google Scholar
PubMed
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China
Search for other papers by Xiulin Shi in
Google Scholar
PubMed
Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, Xiamen, China
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Search for other papers by Menghua Wu in
Google Scholar
PubMed
Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, Xiamen, China
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Search for other papers by Han Li in
Google Scholar
PubMed
Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, Xiamen, China
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Search for other papers by Qiuhong Liu in
Google Scholar
PubMed
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Search for other papers by Xiaofang Zhang in
Google Scholar
PubMed
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Search for other papers by Yan Zhao in
Google Scholar
PubMed
Fujian Provincial Key Laboratory of Translational Medicine for Diabetes, Xiamen, China
Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China
Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, Xiamen Diabetes Prevention and Treatment Center, Xiamen, China
Search for other papers by Xuejun Li in
Google Scholar
PubMed
Background
Fibrosis is an important pathological process in the development of non-alcoholic steatohepatitis (NASH), and the activation of hepatic stellate cell (HSC) is a central event in liver fibrosis. However, the transcriptomic change of activated HSCs (aHSCs) and resting HSCs (rHSCs) in NASH patients has not been assessed. This study aimed to identify transcriptomic signature of HSCs during the development of NASH and the underlying key functional pathways.
Methods
NASH-associated transcriptomic change of HSCs was defined by single-cell RNA-sequencing (scRNA-seq) analysis, and those top upregulated genes were identified as NASH-associated transcriptomic signatures. Those functional pathways involved in the NASH-associated transcriptomic change of aHSCs were explored by weighted gene co-expression network analysis (WGCNA) and functional enrichment analyses. Key regulators were explored by upstream regulator analysis and transcription factor enrichment analysis.
Results
scRNA-seq analysis identified numerous differentially expressed genes in both rHSCs and aHSCs between NASH patients and healthy controls. Both scRNA-seq analysis and in-vivo experiments showed the existence of rHSCs (mainly expressing a-SMA) in the normal liver and the increased aHSCs (mainly expressing collagen 1) in the fibrosis liver tissues. NASH-associated transcriptomic signature of rHSC (NASHrHSCsignature) and NASH-associated transcriptomic signature of aHSC (NASHaHSCsignature) were identified. WGCNA revealed the main pathways correlated with the transcriptomic change of aHSCs. Several key upstream regulators and transcription factors for determining the functional change of aHSCs in NASH were identified.
Conclusion
This study developed a useful transcriptomic signature with the potential in assessing fibrosis severity in the development of NASH. This study also identified the main pathways in the activation of HSCs during the development of NASH.
Department of Endocrinology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Search for other papers by Chenmin Wei in
Google Scholar
PubMed
Search for other papers by Zichen Zhang in
Google Scholar
PubMed
Search for other papers by Qi Fu in
Google Scholar
PubMed
Search for other papers by Yunqiang He in
Google Scholar
PubMed
Search for other papers by Tao Yang in
Google Scholar
PubMed
Search for other papers by Min Sun in
Google Scholar
PubMed
Objective
Lipotoxicity-induced pancreatic β cell-dysfunction results in decreased insulin secretion in response to multiple stimulus. In this study, we investigated the reversible effects of palmitate (PA) or oleate (OA) on insulin secretion and the relationship with pancreatic β-cell ATP-sensitive potassium (KATP) channels.
Methods
MIN6 cells were treated with PA and OA for 48 h and then washed out for 24 h to determine the changes in expression and endocytosis of the KATP channels and glucose-stimulated insulin secretion (GSIS) and sulfonylurea-stimulated insulin secretion (SU-SIS).
Results
MIN6 cells exposed to PA or OA showed both impaired GSIS and SU-SIS; the former was not restorable, while the latter was reversible with washout of PA or OA. Decreased expressions of both total and surface Kir6.2 and SUR1 and endocytosis of KATP channels were observed, which were also recoverable after washout. When MIN6 cells exposed to free fatty acids (FFAs) were cotreated with 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) or dynasore, we found that endocytosis of KATP channels did not change significantly by AICAR but was almost completely blocked by dynasore. Meanwhile, the inhibition of endocytosis of KATP channels after washout could be activated by PIP2. The recovery of SU-SIS after washout was significantly weakened by PIP2, but the decrease of SU-SIS induced by FFAs was not alleviated by dynasore.
Conclusions
FFAs can cause reversible impairment of SU-SIS on pancreatic β cells. The reversibility of the effects is partial because of the changes of expression and endocytosis of Kir6.2 and SUR1 which was mediated by dynamin.
Search for other papers by Hoda Gad in
Google Scholar
PubMed
Search for other papers by Einas Elgassim in
Google Scholar
PubMed
Department of Internal Medicine, Albany Medical Center Hospital, Albany, New York, USA
Search for other papers by Ibrahim Mohammed in
Google Scholar
PubMed
Search for other papers by Ahmad Yaser Alhaddad in
Google Scholar
PubMed
Search for other papers by Hussein Ahmed Hussein Zaky Aly in
Google Scholar
PubMed
Search for other papers by John-John Cabibihan in
Google Scholar
PubMed
Search for other papers by Abdulaziz Al-Ali in
Google Scholar
PubMed
Search for other papers by Kishor Kumar Sadasivuni in
Google Scholar
PubMed
Search for other papers by Aliyaa Haji in
Google Scholar
PubMed
Search for other papers by Neila Lamine in
Google Scholar
PubMed
Search for other papers by Adnan Khan in
Google Scholar
PubMed
Search for other papers by Ioannis N Petropoulos in
Google Scholar
PubMed
Search for other papers by Georgios Ponirakis in
Google Scholar
PubMed
Search for other papers by Alise Kalteniece in
Google Scholar
PubMed
Search for other papers by Maryam Ferdousi in
Google Scholar
PubMed
Search for other papers by Shazli Azmi in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Royal Liverpool and Broadgreen University NHS Hospital Trust, Liverpool, UK
Division of Endocrinology, Diabetes and Gastroenterology, University of Manchester, Manchester, UK
Search for other papers by Uazman Alam in
Google Scholar
PubMed
Search for other papers by Wajeeha Abuhelaiqa in
Google Scholar
PubMed
Search for other papers by Amin Jayyousi in
Google Scholar
PubMed
Search for other papers by Dabia AlMohanadi in
Google Scholar
PubMed
Search for other papers by Khaled Baagar in
Google Scholar
PubMed
Institute of Cardiovascular Medicine, University of Manchester, Manchester, UK
Search for other papers by Rayaz A Malik in
Google Scholar
PubMed
Objective
Continuous glucose monitoring (CGM) has revealed that glycemic variability and low time in range are associated with albuminuria and retinopathy. We have investigated the relationship between glucose metrics derived from CGM and a highly sensitive measure of neuropathy using corneal confocal microscopy in participants with type 1 and type 2 diabetes.
Methods
A total of 40 participants with diabetes and 28 healthy controls underwent quantification of corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), corneal nerve fiber length (CNFL) and inferior whorl length (IWL) and those with diabetes underwent CGM for four consecutive days.
Results
CNBD was significantly lower in patients with high glycemic variability (GV) compared to low GV (median (range) (25.0 (19.0–37.5) vs 38.6 (29.2–46.9); P = 0.007); in patients who spent >4% compared to <4% time in level 1 hypoglycemia (54-69 mg/dL) (25.0 (22.9–37.5) vs 37.5 (29.2–46.9); P = 0.045) and in patients who spent >1% compared to <1% time in level 2 hypoglycemia (<54 mg/dL) (25.0 (19.8–41.7) vs 35.4 (28.1–44.8); P = 0.04). Duration in level 1 hypoglycemia correlated with CNBD (r = –0.342, P = 0.031). Duration in level 1 (181–250 mg/dL) and level 2 (>250 mg/dL) hyperglycemia did not correlate with CNFD (P > 0.05), CNBD (P > 0.05), CNFL (P > 0.05) or IWL (P > 0.05).
Conclusions
Greater GV and duration in hypoglycemia, rather than hyperglycemia, are associated with nerve fiber loss in diabetes.
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Objective
Pasireotide is a second-generation somatostatin receptor ligand (SRL) used for treating acromegaly. Its clinical use is limited by adverse effects on glucose homeostasis. The aim of this study was to evaluate longitudinal changes in beta-cell function and insulin sensitivity associated with pasireotide in patients not controlled by first-generation SRLs.
Design
We performed a retrospective study.
Methods
The efficacy (growth hormone (GH)/insulin-like growth factor (IGF-1) concentrations; tumor size) and effect on glucose homeostasis were analyzed in 33 patients. Longitudinal data on oral glucose tolerance tests were available before, shortly (mean ± s.d., 6.1 ± 3.8 months) and long term (24.4 ± 11.1 months) after initiation of pasireotide in 14 patients. Insulin secretion (insulinogenic index; disposition index) and insulin sensitivity were calculated by validated indices.
Results
Pasireotide-induced diabetes occurred in 12 patients (36%). It was mediated by impaired insulin secretion, which occurred shortly after initiation of treatment and then remained stable on long term (insulinogenic index, median (min; max), 80 (12; 542) vs 16 (6.4; 101) vs 25 (3.7; 396) pmol/mmol, respectively; P = 0.028; disposition index, 1.45 (0.42; 4.88) vs 0.53 (0.17; 2.63) vs 0.60 (0.22; 1.71), respectively; P = 0.024). No significant changes in insulin sensitivity were observed, despite a marked reduction of GH/IGF-1 concentrations. Older age and a worse glycemic control at baseline were the strongest predictors for hyperglycemia and the need for antidiabetic treatment.
Conclusion
Worsening of glycemic control during pasireotide therapy is caused by an impaired insulin secretion, whereas insulin sensitivity is not affected. These findings might be important for the choice of antidiabetic treatment for pasireotide-induced hyperglycemia.
Significance statement
Pasireotide, a second-generation SRL used for treating acromegaly, may be associated with glucose metabolism impairment. In a retrospective study of 33 patients, we observed that treatment with pasireotide was associated with normalization of serum IGF-1 in almost 60% of patients, but one-third of patients developed diabetes. In the patients who stopped pasireotide because of hyperglycemia, HbA1c promptly decreased. Longitudinal data in 14 patients show that diabetes is mediated by impaired insulin secretion, which occurred shortly and then remained stable on long term, while no significant changes in insulin sensitivity were observed, despite a marked reduction of GH/IGF-1 concentrations. Older age and a worse glycemic control at baseline were the strongest predictors for hyperglycemia.
